Abstract miRNAs (microRNAs) are important regulatory molecules that control gene expression in all eukaryotes. miRNAs play an essential role in basic cellular activities such as proliferation, differentiation, morphogenesis and apoptosis. In haemopoiesis, several miRNA-based pathways have been identified. Importantly, miRNA mutations or mis-expression correlate with various human diseases. In cancer, deregulated miRNAs can function as tumour suppressors or oncogenes. The present review focuses on the recent literature concerning the role of miRNAs in three different research areas: haematology, cardiology and oncology, with particular focus on the results obtained by our group.
Introduction
miRNAs (microRNAs) are a rapidly expanding class of short (∼22 nt) single-stranded non-coding RNAs [1, 2] . miRNAs can be encoded in independent transcription units, in polycistronic clusters or within the introns of proteincoding genes [1, 2] . Most miRNAs are transcribed by RNA polymerase II as capped and polyadenylated pri-miRNAs (primary miRNAs) that contain extended hairpin structures. A pri-miRNA is cleaved in the nucleus by the RNase III enzyme Drosha, thus releasing the ∼65 nt long pre-miRNA (precursor miRNA). A pre-miRNA is exported in the cytoplasm by exportin-5 where it is processed further by the RNAse III Dicer, which excises a 19-25-nt doublestranded duplex. This short duplex is incorporated into the miRISC (miRNA-induced silencing complex), where the mature miRNA strand is preferentially retained. The miRISC is directed to the 3 -UTR (untranslated region) of mRNAs that are complementary to its miRNA component. Pairing of the miRNA with the 3 -UTR interferes with the translation and/or stability of the target mRNA, thus leading to the repression of protein expression [3] . miRNAs play important roles in the regulation of basic cell functions, including development, proliferation, differentiation and apoptosis [4, 5] , whereas deregulation of miRNAs can lead to oncogenesis.
In the present paper, we describe the most relevant findings on the role of miRNAs in normal haemopoiesis, heart hypertrophy and cancer, with particular focus on the results obtained by our group.
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miRNAs and normal haemopoiesis
Haemopoiesis is sustained by continuous differentiation of multipotent HSCs (haemopoietic stem cells) into HPCs (haemopoietic progenitor cells), giving rise to different lineages and mature blood cells. Regulation of haemopoiesis consists of two aspects: the self-renewal of HSCs and the differentiation of HSCs/HPCs, i.e. their progressive restriction of lineage potential and their development into differentiated precursors up to mature terminal cells [6] . HSC differentiation leads to the formation of multipotent cells, which have largely lost the self-renewal ability, but retain the ability to differentiate into all types of blood cell. These HPCs generate CLPs (common lymphoid progenitors), giving rise to T-and B-lymphocytes and CMPs (common myeloid progenitors), which generate erythrocytes and megakaryocytes deriving from an MEP (megakaryocyte-eythroid progenitor), and granulocytes and monocytes/macrophages descending from a GMP (granulomonocytic progenitor) [6] .
The first study describing a role of miRNAs in haemopoietic differentiation reported in 2004 that three miRNAs (miR-142, miR-181 and miR-223) are specifically expressed and dynamically regulated in haemopoietic cells [7] . Subsequently, several miRNA-based pathways underlying haemopoietic differentiation were identified.
During human erythropoiesis, miR-221/222, clustered on the X chromosome, are highly expressed in CD34 + HPCs and are gradually and sharply down-modulated during unilineage erythroid differentiation [8] . The decline of miR-221 and miR-222 during exponential erythroid growth unblocks c-kit protein production at the mRNA level; since c-kit is the receptor of the kit ligand or SCF (stem cell factor), this leads to expansion of early erythroblasts. Two recent studies identified two additional pathways essential for human erythropoiesis: a report focused on miR-24, a negative regulator that inhibits erythroid differentiation by targeting activin type I receptor ALK4 [9] . The second study identified a GATA1-regulated miRNA locus, comprising miR-144 and miR-451, which is required for erythroid development in zebrafish embryos [10] .
In MEPs, miR-150 was found to drive in vitro and in vivo megakaryocytic differentiation at the expense of the erythroid lineage. This work established a role for miRNAs in lineage specification of multipotent cells [11] .
A regulatory pathway in megakaryopoiesis, involving the PLZF (promyelocytic leukaemia zinc finger) transcription factor, miR-146a and the SDF-1 (stromal-cell-derived factor 1) receptor CXCR4 has been identified recently [12] . miR-146a was initially observed to be an endotoxinresponsive gene in human monocytes [13] , whereas the PLZF protein is a transcription factor involved in the regulation of development, haemopoietic proliferation and differentiation, leukaemogenesis and tumorigenesis [14] . This new identified pathway involves PLZF that transcriptionally inhibits miR-146a, which in turn regulates CXCR4. In megakaryopoietic cultures of CD34 + HPCs, PLZF was up-regulated, whereas miR-146a expression decreased and CXCR4 protein increased. miR-146a overexpression as well as PLZF or CXCR4 silencing impaired megakaryocyte proliferation, differentiation and maturation, and megakaryocyte colony formation.
The key role of miRNA in human monocytopoiesis was demonstrated in two separate studies. The first one investigated the role of miRNAs pertaining to the miR-17-5p-92 and miR-106a-92 clusters in monocytic differentiation [15] . miR-17-5p-92 is a cluster of seven miRNAs on chromosome 13, transcribed as a polycistronic unit [16] . This cluster is highly homologous with the miR-106a-92 and the miR106b-25 clusters located on chromosome X and 7 respectively [17] . During monocytic differentiation, low levels of miR-17-5p/20a/106a allow translation of AML1 (acute myeloid leukaemia 1) that transcriptionally inhibits the miR-17-5p-92 and miR-106a-92 clusters and transactivate the expression of the M-CSF (monocyte colony-stimulating factor) receptor (i.e. the pivotal regulator of monocytopoiesis), thus inducing monocytic cell differentiation. Therefore this study indicated that monocytopoiesis is controlled by a circuitry involving sequentially miR-17-5p/20a/106a, AML1 and M-CSF receptor, whereby miR-17-5p/20a/106a function as a master gene complex interlinked with AML1 in a mutual negativefeedback loop [15] . Interestingly, the miR-17-92 cluster is also essential for B-lymphocyte development in vivo; targeted deletion of this cluster resulted in lung hypoplasia and inhibition of the pro-B to pre-B transition [18] . On the other hand, transgenic expression of the miR-17-92 cluster in mice caused the development of lymphoproliferative disease and autoimmunity [19] .
An additional miRNA-based PU.1-dependent regulatory pathway which is required to execute the normal human monocytic differentiation programme was described recently [20] . It was found that the master transcription factor PU.1 directly activates miR-424 transcription during monocytic differentiation of promyelocytic blasts as well as human HPCs in unilineage monocytic culture. miR-424 resulted as a potent inducer of monocytic differentiation, at least in part by targeting the transcription factor NFI-A (nuclear factor I-A), whose down-regulation is critical for progression to monocytic differentiation [20] .
miRNAs have also been linked to macrophage functions during inflammation and innate immunity. miR-155 was found to be up-regulated in primary murine macrophages after exposure to IFNβ (interferon β) and poly(I:C) [21] . Sustained expression of miR-155 in HSCs was shown to cause myeloproliferative disorder, originated by an abnormal expansion of the GMP pool, in a manner reminiscent of LPS (lipopolysaccharide) treatment [22] . Moreover, miR-155's functional association with the immune system was exploited further in three different in vivo models. Using genetic deletion and transgenic approaches, Klaus Rajewsky's group showed the important role of miR-155 in regulating helper T-cell differentiation and the germinal centre reaction to produce T-cell-dependent antibody response [23] . Mice lacking miR-155 are immunodeficient and display increased lung airway remodelling, owing to impaired functions of B-and T-lymphocytes and dendritic cells [24] . Finally, B-cells lacking miR-155 generated reduced extrafollicular and germinal centre responses, and failed to produce high-affinity IgG1 antibodies in response to thymus-dependent and -independent antigens [25] .
Using a loss-of-function allele in mice, the transcriptional induction of the myeloid-specific miR-223 was found to be responsible for progenitor proliferation and granulocyte function in vivo [26] . Similarly, miR-223 was found to be part of a circuitry that involves two transcriptional factors, NFI-A and C/EBPα (CCAAT/enhancer-binding protein α) in the RA (retinoic acid)-induced differentiation of a promyelocytic cell line [27] .
Collectively, these findings establish a central role for miRNAs in the fine-tune regulation of the haemopoietic gene expression programme.
miRNAs and heart hypertrophy
Heart failure is a syndrome caused by diminished heart function that arises from pathologies such as hypertension, infarction and diabetes. In most forms of heart failure, development of the disorder is associated with an alteration of cardiomyocyte structure, including an increase in heart mass due to cell hypertrophy. miRNAs have been demonstrated to be directly involved in heart disease development [28, 29] . For example, miR-1 and miR-133, which belong to the same transcriptional unit, have been shown to play a critical role in determining cardiomyocyte hypertrophy [28] . They are expressed at low levels in mouse and human models of cardiac hypertrophy, whereas their overexpression can inhibit cardiac hypertrophy. Importantly, in vivo inhibition of miR-133 by a single infusion of an antagomir causes marked and sustained cardiac hypertrophy [28] . This occurs through the regulation of different targets: RhoA, a GDP-GTP exchange protein regulating cardiac hypertrophy; Cdc42, a signal transduction kinase implicated in hypertrophy; and Nelf-A (negative elongation factor A)/WHSC2 (Wolf-Hirschhorn syndrome candidate 2), a nuclear factor involved in cardiogenesis. These studies show that miR-133, and possibly miR-1, are key regulators of cardiac hypertrophy, suggesting their fundamental role in the development of disease and, as such, potential targets and/ or agents of novel therapies.
miRNAs and cancer
Oncogenesis has been linked to deregulated expression of miRNAs, which can act as tumour suppressors or oncomirs [30] . The crucial role of miRNAs in cancer progression is supported by the observation that a large number of miRNA genes are located in genomic regions that are frequently amplified, deleted or rearranged in cancer [31] . The oncogenic role of several miRNAs, including let-7, miR-21, miR-155, miR-34 and the miR-17-5p-92 cluster, has been well established [30] . In addition, miRNAs involved in tumour invasion and metastasis have been identified [32] [33] [34] .
miR-34 is a well-documented example of an miRNA that behaves as a tumour suppressor. Initial studies showed that miR-34 family members (including miR-34a/b/c) are key transcriptional targets of p53 [35] [36] [37] [38] . Analysis of miR-34 levels in different types of tumour showed a down-modulation of these miRNAs in colon cancer [39] , non-small cell lung cancers [37] and pancreatic cancer cells [38] . In addition, miR-34a, which is located in a genomic region (1p36) that is frequently deleted in advanced neuroblastoma, has been shown to be expressed at low levels in primary neuroblastoma [40] . miR-34a acts as a tumour-suppressor gene: indeed, ectopic expression of miR-34 induces growth arrest both in vitro and in vivo, whereas inactivation of miR-34 strongly attenuates p53-mediated apoptosis [35] [36] [37] [38] [39] [40] . Several targets of miR-34 involved in cell-cycle regulation and apoptosis, including E2F3 [39, 40] and Bcl-2 [37] , have been identified, thus providing insights into the molecular mechanism underlying miR-34 oncogenic activity.
The miR-17-5p-92 cluster (also called oncomir-1) was the first miRNA with oncogenic properties to be discovered [41] . In a first study, the Hannon and Hammond laboratories showed that overexpression of the miR-17-5p-92 cluster in Eμ-myc transgenic mice dramatically accelerated B-cell lymphoma onset and progression [41] . Furthermore, overexpression of the miR-17-92 cluster promotes neovascularization by targeting Tsp1 (thrombospondin-1) and CTGF (connective tissue growth factor) [42] . Growing evidence documents deregulation of the miR-17-5p-92 cluster in cancer. Specifically, a genomic region containing the miR-17-5p-92 polycistron is amplified in B-cell lymphomas [41] , whereas the miR-17-5p-92 cluster is overexpressed in diverse types of tumour, including both haemopoietic malignancies and solid tumours such as breast, colon, lung, pancreas, prostate and stomach [43] [44] [45] [46] , Transcription of the miR-17-5p-92 cluster is regulated by the oncogene c-Myc [47] and two regulators of cell-cycle progression, E2F1 and E2F3 [48, 49] . Interestingly, miRNAs pertaining to the miR-17-5p-92 cluster regulate E2F1, E2F2 and E2F3, thus establishing a negative-feedback loop [47] [48] [49] . In addition to E2Fs other direct targets of miR-17-5p-92, miR-106a-92 and miR-106b-25 clusters have been identified that control cell-cycle progression and apoptosis, including CDKN1A (cyclin-dependent kinase inhibitor 1A) (p21) [45, 50] and Bcl2L11 (Bcl-2-like 11)/Bim [18, 19, 45, 50] . Recently, the oncogenic role of the miR-17-5p-92 cluster in neuroblastoma development has been established [50] . Neuroblastoma is one of the most common paediatric tumours, accounting for >15% of cancerrelated deaths in children. Amplification of the MYCN gene is the best characterized genetic marker correlating with aggressive and therapy-resistant neuroblastoma. However, how MYCN exerts its oncogenic function in neuroblastoma was unknown. This work describes a key oncogenic pathway underlying neuroblastoma development, whereby MYCN, expressed at an elevated level, transactivates the miR-17-5p-92 cluster, which inhibits p21 and Bim translation by interaction with their mRNA 3 -UTRs [50] . Overexpression of the miR-17-5p-92 cluster in MYCN-not-amplified neuroblastoma cells strongly augments their in vitro and in vivo tumorigenesis. In addition, this work describes for the first time the in vivo anti-tumour effect of antagomirs. Indeed, in vitro or in vivo treatment with antagomir-17-5p abolishes the growth of MYCN-amplified and therapyresistant neuroblastoma. The anti-tumour effect obtained with antagomir-17-5p treatment is extremely promising and raises the possibility that these molecules may ultimately be clinically useful in the treatment of cancer.
Conclusions
We have discussed the fundamental contribution of miRNAs for normal haemopoietic differentiation and the consequences of miRNAs deregulation in heart hypertrophy. Moreover, we have remarked on the association of miRNA deregulation and neoplastic transformation. Some miRNAs, such as miR-155 and the miR-17-5p-92 cluster, are critical regulators of normal cell differentiation and can initiate tumorigenesis and act as oncogenes.
The involvement of miRNAs in the regulation of gene expression has been established for virtually any biological processes and several human diseases. Despite that, a deeper understanding of their basic functions and pathological alterations is needed to pave the way for future clinical applications.
